Myeloid hyperplasia
Also known as: Hyperplasia, Hyperplastic, Hypertrophic, Hypertrophy
Methodology & AI Transparency ⓘ
Myeloid hyperplasia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Clinical coding for Myeloid hyperplasia uses ICD-10 D75.89 across Blood & Anemia specialty care.
- 3 Typical cash cost range: Primary evaluation for Myeloid hyperplasia incorporates reticulocyte index [Myeloid hyperplasia D75.89] and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Myeloid hyperplasia: Platelet Count & in Myeloid hyperplasia (D75.89: PT/INR / aPTT) (Platelets 150–400 x10^3/uL (D75.89)) and Hemoglobin, Hematocrit & in Myeloid hyperplasia (D75.89: MCV).
Ask our AI Specialists anything about Myeloid hyperplasia
What Is Myeloid hyperplasia?
Recognized across U.S. clinical coding as D75.89 (Blood & Anemia), Myeloid hyperplasia (also termed Hyperplasia or Hyperplastic) is evaluated via reticulocyte index [Myeloid hyperplasia D75.89] to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in blood & anemia, Myeloid hyperplasia (D75.89) involves anticoagulant factors [Myeloid hyperplasia D75.89]. progression correlates with shifts in Platelet Count & in Myeloid hyperplasia (D75.89: PT/INR / aPTT) (Platelets 150–400 x10^3/uL (D75.89)).
Common Symptoms & Clinical Signs
- • Presentation of Myeloid hyperplasia (D75.89): unexplained limb swelling/clotting in Myeloid hyperplasia (D75.89: tendency or recurrent)
- • Secondary Myeloid hyperplasia clinical sign: exertional fatigue, reduced in Myeloid hyperplasia (D75.89: stamina, pale conjunctiva,)
- • Symptom flares in Myeloid hyperplasia correlating with Platelet Count & in Myeloid hyperplasia (D75.89: PT/INR / aPTT) deviation outside Platelets 150–400 x10^3/uL (D75.89)
- • Functional blood & anemia impact requiring reticulocyte index [Myeloid hyperplasia D75.89] evaluation (D75.89)
Myeloid hyperplasia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D75.89 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Anemia, Clotting & Blood Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: Platelet Count & in Myeloid hyperplasia (D75.89: PT/INR / aPTT) | Platelets 150–400 x10^3/uL (D75.89) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Hemoglobin, Hematocrit & in Myeloid hyperplasia (D75.89: MCV) | Hgb 13.5–17.0 (M) / 12.0–15.5 (F) g/dL (D75.89) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin & in Myeloid hyperplasia (D75.89: Transferrin Saturation) | Ferritin 50–150 ng/mL; TSAT 20%–45% (D75.89) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Myeloid hyperplasia
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Progesterone Endometrin, Crinone • RxCUI 260243 | Progesterone | 76% | $0.2361 | $ 9.45 /mo |
| Crinone (Progesterone) Crinone • RxCUI 260243-B00236150 | Progesterone | 74% | $16.0412 | $ 640.00 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Myeloid hyperplasia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid: What a 406-Participant Study Found There was no significant difference between treatments in secondary efficacy endpoints, reflecting a lack of clinical response. Leukemia research • 2024-05-15 • Phase III Randomized Trial | N = 406 | 93/100 | PMID 38499457 ↗ |
| New Insights on Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia:: What a 447-Participant Study Found Common any-grade side effects (≥10% incidence in any arm) were diarrhea (87.0% vs 32.9%), febrile neutropenia (52.8% vs 49.3%), and nausea (52.5% vs 31.5%). Blood advances • 2022-07-26 • Phase III Randomized Trial | N = 447 | 93/100 | PMID 35413116 ↗ |
| New Insights on Glasdegib plus intensive or non-intensive chemotherapy for untreated acute: What a 404-Participant Study Found The addition of glasdegib to either cytarabine and daunorubicin or azacitidine did not significantly improve overall survival and the primary efficacy endpoint for the BRIGHT AML 1019 phase 3 trial was not met. Leukemia • 2023-10-15 • Phase III Randomized Trial | N = 404 | 93/100 | PMID 37604981 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of ferric carboxymaltose infusion in reducing anemia in Common side effects in the FCM arm included neutropenia (17%), hypophosphatemia (16%), and fatigue (15%). American journal of hematology • 2021-12-01 • Phase III Randomized Trial | N = 122 | 88/100 | PMID 34653287 ↗ |
| Can This Approach Help? Inside the Latest Research on Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute Limited survival benefit in the Japanese subgroup can be attributed to small patient numbers and to baseline imbalances observed between treatment arms, with more patients in the venetoclax plus low-dose cytarabine arm presenting. Japanese journal of clinical oncology • 2021-08-30 • Phase III Randomized Trial | N = 27 | 88/100 | PMID 34322703 ↗ |
Myeloid hyperplasia Patient Community & “People Like Me” Threads
Filter Myeloid hyperplasia community threads and patient logs by age, biological sex, dosage, and treatment duration.